Form 4: CalciMedica Director Alan Glicklich Acquires Stock Options

Director Alan Glicklich of CalciMedica, Inc. was granted stock options for 20,000 shares on January 15, 2025.

Summary

• Alan Glicklich, a director at CalciMedica, Inc., was granted stock options to purchase 20,000 shares of common stock.
• The options were granted on January 15, 2025, at an exercise price of $3.02 per share.
• The options vest monthly over a three-year period, starting from the grant date.
• The options expire on January 14, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly listed companies.
• The vesting period of three years is typical for such grants, aligning with long-term value creation.
• The exercise price of $3.02 is a specific value for this grant and would need to be compared to other grants to determine if it is in line with industry standards.

Stakeholder Impact

• The stock option grant could positively impact shareholders by aligning the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, director, CalciMedica, insider trading, equity, vesting